ROCKVILLE, Md., Aug. 3, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Method of Achieving a Thymosin Beta 4 Concentration in a Human Patient. The patent covers treating a patient with a desired concentration of Thymosin Beta 4 (Tβ4) over a period of time, as well as treating a patient by maintaining a desired concentration of Tβ4 in a pharmacologically effective range. The patent expiry will be in late 2031, or longer depending on any extensions available from the USPTO.
"This is an important patent for RegeneRx as it is expected to provide expanded coverage and extended exclusivity for the administration of Tβ4 for the treatment of patients with cardiac and central nervous disorders, which are areas of significant interest for the Company. Management and patent counsel have worked hard on obtaining this patent and it is a significant achievement under our complex and ever-changing patent laws," stated J.J. Finkelstein, RegeneRx's president and chief executive officer.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries throughout the world. RGN-259, the Company's Tβ4-based ophthalmic drug candidate, has been designated an orphan drug in the U.S. for the treatment of neurotrophic keratopathy (NK). In September 2015, RegeneRx, through its U.S joint venture, ReGenTree LLC, initiated a Phase 2/3 clinical trial in patients with dry eye syndrome and a Phase 3 clinical trial in patients with NK. The dry eye trial has been completed and results should be announced shortly. RGN-259 is also being developed in patients with dry eye syndrome in Asia through RegeneRx's two Asian partnerships. RGN-352, the Company's Tβ4-based injectable formulation, is a Phase 2-ready drug candidate designed to be administered systemically to prevent and repair central nervous system tissue damage associated disorders such as multiple sclerosis and traumatic injuries such as stroke. For additional information about RegeneRx please visit www.regenerx.com.
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can be no assurance that any notices or patents issued by the USPTO, or licenses held by the Company, or patent applications filed by the Company, including this most recent Notice of Allowance in the U.S., or any current or future clinical trials will result in approved products or future value. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2015, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regenerx-receives-notice-of-allowance-for-key-us-patent-that-expands-and-extends-exclusivity-of-companys-product-candidates-300308597.html
SOURCE RegeneRx Biopharmaceuticals, Inc.